Conservative Balance Sheet (zero Debt)Zero reported debt materially reduces insolvency and interest-service risk for a cash-burning biotech. This structural conservatism preserves strategic optionality and negotiating leverage when raising capital, extending runway and lowering refinancing pressure over the medium term.

Very High Gross Margins On RevenueExtremely high gross margins on recorded revenue indicate strong unit economics once sales scale. That structural margin profile supports long-term operating leverage and attractive profitability potential if R&D converts to commercial products and fixed costs are absorbed.

Focus On Engineered Cell ImmunotherapiesProprietary cell-engineering focus positions the company within structural growth of immunotherapies and cell therapeutics. A differentiated technology platform can create sustainable competitive advantages and multi-product optionality if clinical progress and IP protection hold.

Bears Say

Persistent Negative Cash Flow And Rising Cash BurnConsistent operating and free cash flow deficits, with accelerating 2024 burn, create tangible runway and financing risk. Over 2–6 months this structural cash gap necessitates external capital, increasing dilution risk and constraining long-term R&D and development timelines.

Deteriorating Revenue And Widening LossesA declining and volatile revenue base alongside widening operating losses signals weak commercial traction and unsustainable expense base. Structurally, this limits ability to self-fund development, undermines scalable growth prospects, and increases dependency on dilutive financing.

Declining Equity And Negative Returns On EquityFalling shareholders' equity and persistently negative ROE indicate erosion of owner value from recurring losses. This structural deterioration reduces financial resilience, makes future fundraising more dilutive, and signals potential long-term governance or capital allocation challenges.

4893 FAQ

What was Noile-Immune Biotech Inc.’s price range in the past 12 months?

Noile-Immune Biotech Inc. lowest stock price was ¥120.00 and its highest was ¥214.00 in the past 12 months.

What is Noile-Immune Biotech Inc.’s market cap?

Noile-Immune Biotech Inc.’s market cap is ¥6.66B.

When is Noile-Immune Biotech Inc.’s upcoming earnings report date?

Noile-Immune Biotech Inc.’s upcoming earnings report date is May 19, 2026 which is in 90 days.

How were Noile-Immune Biotech Inc.’s earnings last quarter?

Noile-Immune Biotech Inc. released its earnings results on Feb 13, 2026. The company reported -¥4.36 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.36.

Is Noile-Immune Biotech Inc. overvalued?

According to Wall Street analysts Noile-Immune Biotech Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Noile-Immune Biotech Inc. pay dividends?

Noile-Immune Biotech Inc. does not currently pay dividends.

What is Noile-Immune Biotech Inc.’s EPS estimate?

Noile-Immune Biotech Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Noile-Immune Biotech Inc. have?

Noile-Immune Biotech Inc. has 43,276,764 shares outstanding.

What happened to Noile-Immune Biotech Inc.’s price movement after its last earnings report?

Noile-Immune Biotech Inc. reported an EPS of -¥4.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.938%.

Which hedge fund is a major shareholder of Noile-Immune Biotech Inc.?

Currently, no hedge funds are holding shares in JP:4893

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Noile-Immune Biotech Inc.

Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.